Aspetar Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2009
NCT01812564
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Aspetar | Aspetar Orthopeadic and Sports Medicine Hospital | Aspetar, Orthopedic and Sports Medicine Hospital

Active Ingredients

Drugs in Phase 2 Trials (1)

platelet poor plasma (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Sprains and Strains (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1